The Bronx Blood Research Fund provides excellence in research and advances therapy and management of the thalassemias and the hemoglobinopathies.
With combined resources from the Montefiore (Moses) and Einstein campuses, the Division of Hematology's history of excellence in scientific investigation includes funded research in embryonic stem cell investigations, high-throughput red blood cell engineering, chemically modified hemoglobins and albumin, in vitro red blood cell production, murine models of sickle cell disease, the role of nitric oxide and inflammation on microcirculation, plasma expanders, genetics, hemoglobin disorders, thrombosis, and hemostasis.
Henny Billett, M.D., M.Sc., FACP
Risk factors for thrombosis and microvascular disease, effect of race and ethnicity on thrombosis, thrombotic and microvascular complications of sickle cell disease.
Eric Bouhassira, Ph.D.
Hematopoietic (blood-forming) stem cells that can differentiate into red cells, T cells, platelets, and all other cell types that comprise blood.
Michael B. Stemerman, M.D.
LDL alters the function of the vascular endothelium and this alteration may be an important mechanism for the development of atherosclerosis.
Neeraja Danda, Ph.D.
Deepti Virmani, Ph.D.